Iris Lansdorp-Vogelaar

Review updates and current considerations in colon cancer screening and surveillance related topics…

Review updates and current considerations in colon cancer screening and surveillance related topics…

Review updates and current considerations in colon cancer screening and surveillance related topics…

In the Dutch colorectal cancer (CRC) screening program, individuals aged 55 to 75 years are invited biennially for fecal immunochemical test (FIT)-based screening using a positivity cut-off of 47 microgram Hemoglobin per gram feces (µg Hb/g)…

In the Dutch colorectal cancer (CRC) screening program, individuals aged 55 to 75 years are invited biennially for fecal immunochemical test (FIT)-based screening using a positivity cut-off of 47 microgram Hemoglobin per gram feces (µg Hb/g)…

Colonoscopy surveillance intervals are based on the predicted risk of metachronous colorectal cancer (CRC) after polyp removal. Due to the presence of co-existent findings at baseline colonoscopy, risk estimation per specific polyp subtype is difficult…

Gastric cancer (GC) incidence is declining and too low in the US to recommend general population screening. However, the risk of developing GC in the US is substantially higher in ethnic minorities, potentially warranting screening in specific population subgroups. While _H…

BACKGROUND: Evidence of gastric cancer (GC) screening’s impact on GC incidence remains limited, hindering the development of health policies for screening programs. We aimed to assess the population impact of organized GC screening programs on GC incidence in Seoul, South Korea…

SOCIETY: AGA CP…

A blood-based colorectal cancer (CRC) screening test may increase screening participation. However, blood-based screening tests may be less effective than current guideline-endorsed options…

Blood-based biomarker tests have been developed as a non-invasive colorectal cancer (CRC) screening method to triage patients to colonoscopy…

In 2019, a BMJ Rapid Recommendation panel judged that for adults with a predicted 15-year risk of CRC below 3%, the benefits of colorectal cancer (CRC) screening would not outweigh the burdens and potential harms. The panel recommended against CRC screening for these individuals…

Prior studies showed that the benefits, harms, and costs of colorectal cancer (CRC) screening at older ages highly depend on a patient's sex, health, and screening history. However, these studies were not directly informed by stratified data on CRC risk…

Most colorectal cancer (CRC) screening programs use a uniform screening strategy. However, it may be more efficient to screen males and females differently due to (ambivalent) biological and demographic differences between the sexes…

Colorectal cancer (CRC) screening programmes have been shown effective in reducing CRC incidence and mortality. Risk stratification offers opportunities for further optimisation of screening programmes by better balancing the harms and benefits of screening…

There is growing evidence that the balance between harms and benefits of colorectal cancer (CRC) screening can be improved using risk stratification…